Dual Eligibles: Medicaid Enrollment and Spending for Medicare Beneficiaries in 2007

Provides an update on the share of total Medicaid enrollment and spending on those eligible for both Medicare and Medicaid through 2007, state-by-state estimates of Medicaid enrollment and expenditures for dual eligibles, and a breakdown of expenditures

You\u27re a Good Man, Charlie Brown Playbill

Providence College Department of Theater, Dance & Film The Friar\u27s Cell (Basement of Stephens) You\u27re a Good Man, Charlie Brown December 2-5 + 9-11, 1971 8:00pm Director, R.L. Pelkington, O.P. Assistant Director, John Garrity Music Director, J.L. Prest, O.P. Cast: Charlie Brown - Thomas Rubino, Lucy - Alex Tavares, Snoopy - James Hughes, Patty - Chris Mahoney, Linus - Michael Allen, Schroeder - Vincent Clarkhttps://digitalcommons.providence.edu/charliebrown_1971_pubs/1001/thumbnail.jp

The insulin-like growth factor system : a target for endocrine disruptors?

Acknowledgments: Figures were created with BioRender.com Funding: This work was supported by the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie project PROTECTED (grant agreement No. 722634) and FREIA project (grant agreement No. 825100). The authors declare no conflicts of interest regarding this studyPeer reviewedPublisher PD

Generation and characterisation of antibodies specific for the multidrug resistance-associated protein, MRP

Multidrug resistance associated protein 1 (MRP1) is a 190kD integral membrane glycoprotein which belongs to the ATP-binding cassette (ABC) superfamily of transport proteins. The MRP1 specific MAbs, MRPrl, MRPm6 and QCRL-1 have facilitated both clinical and experimental investigations of this protein to date. In this thesis we have used various types of MRP 1-related immunogens in various species and utilising different immunisation protocols with the objective of producing additional MRP1 specific MAbs which might detect different epitopes Immunogens used included short synthetic peptides, fusion protems and MRP1 over-expressmg cells Species used for immunisation included New Zealand White rabbits, Balb\c mice and Wistar rats. A number of immunisation routes, such as mtrapentoneal, subcutaneous and the lymphatic system via footpad injections were used Variations in immunisation protocols included in-vivo and in-vitro immunisations

Previous pregnancies among young women having an abortion in England and Wales

Purpose: The purpose of this study is to use national statistics on abortions carried out in England and Wales to more precisely estimate the proportion of young women aged under 20 obtaining an abortion who have had one or more previous pregnancies. Methods: Secondary analysis of abortion data from the Office of National Statistic and the Department of Health by parity for women under 20, ordinarily residing in England and Wales, from 1992 - 2013. Results: Over the last 20 years, the proportion of teenagers in England and Wales having an abortion as a result of a subsequent pregnancy increased by 33% (from 0.172 in 1992 to 0.229 in 2013). The majority of this increase occurred prior to 2004 and the proportion now appears to have stabilised. In 2013, 22.9% of the young women aged under 20 who underwent an abortion had had at least one previous pregnancy (either a birth or an abortion). Only a minority (less than 5% of teenagers who obtained an abortion) had had more than one previous pregnancy. Conclusions: The findings show that nearly one in four teenagers presenting for an abortion have already been in contact with health services for a previous birth or abortion. Greater policy emphasis must be placed on the accurate identification of the proportion of teenage pregnancies that occur as a result of a subsequent pregnancy and developing more effective 'secondary prevention' interventions to help first-time pregnant and parenting teenagers

Validity of a Novel Research-Grade Physical Activity and Sleep Monitor for Continuous Remote Patient Monitoring

In the midst of the COVID-19 pandemic, Remote Patient Monitoring technologies are highly important for clinicians and researchers. These connected-health technologies enable monitoring of patients and facilitate remote clinical trial research while reducing the potential for the spread of the novel coronavirus. There is a growing requirement for monitoring of the full 24 h spectrum of behaviours with a single research-grade sensor. This research describes a free-living and supervised protocol comparison study of the Verisense inertial measurement unit to assess physical activity and sleep parameters and compares it with the Actiwatch 2 actigraph. Fifteen adults (11 males, 23.4 ± 3.4 years and 4 females, 29 ± 12.6 years) wore both monitors for 2 consecutive days and nights in the free-living study while twelve adults (11 males, 23.4 ± 3.4 years and 1 female, 22 ± 0 years) wore both monitors for the duration of a gym-based supervised protocol study. Agreement of physical activity epoch-by-epoch data with activity classification of sedentary, light and moderate-to-vigorous activity and sleep metrics were evaluated using Spearman’s rank-order correlation coefficients and Bland–Altman plots. For all activity, Verisense showed high agreement for both free-living and supervised protocol of r = 0.85 and r = 0.78, respectively. For physical activity classification, Verisense showed high agreement of sedentary activity of r = 0.72 for free-living but low agreement of r = 0.36 for supervised protocol; low agreement of light activity of r = 0.42 for free-living and negligible agreement of r = −0.04 for supervised protocol; and moderate agreement of moderate-to-vigorous activity of r = 0.52 for free-living with low agreement of r = 0.49 for supervised protocol. For sleep metrics, Verisense showed moderate agreement for sleep time and total sleep time of r = 0.66 and 0.54, respectively, but demonstrated high agreement for determination of wake time of r = 0.83. Overall, our results showed moderate-high agreement of Verisense with Actiwatch 2 for assessing epoch-by-epoch physical activity and sleep, but a lack of agreement for activity classifications. Future validation work of Verisense for activity cut-point potentially holds promise for 24 h continuous remote patient monitoring